A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
Public ClinicalTrials.gov record NCT00321477. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase IIa study to evaluate the efficacy, safety and tolerability of GW679769 vs placebo on symptoms of urgency with urge incontinence, frequency and nocturia associated with overactive bladder in women.
Study identification
- NCT ID
- NCT00321477
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 160 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 30, 2005
- Primary completion
- Jan 31, 2007
- Completion
- Jan 31, 2007
- Last update posted
- Jan 19, 2017
2005 – 2007
United States locations
- U.S. sites
- 41
- U.S. states
- 20
- U.S. cities
- 39
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | Huntsville | Alabama | 35801 | — |
| GSK Investigational Site | Peoria | Arizona | 85381 - 4828 | — |
| GSK Investigational Site | Phoenix | Arizona | 85023 | — |
| GSK Investigational Site | La Mesa | California | 91942 | — |
| GSK Investigational Site | Modesto | California | 95350 | — |
| GSK Investigational Site | San Bernardino | California | 92404 | — |
| GSK Investigational Site | Torrance | California | 90506 | — |
| GSK Investigational Site | Aurora | Colorado | 80012 | — |
| GSK Investigational Site | Denver | Colorado | 80210 | — |
| GSK Investigational Site | Denver | Colorado | 80211 | — |
| GSK Investigational Site | Longmont | Colorado | 80501 | — |
| GSK Investigational Site | Waterbury | Connecticut | 06708 | — |
| GSK Investigational Site | Aventura | Florida | 33180 | — |
| GSK Investigational Site | Clearwater | Florida | 33761 | — |
| GSK Investigational Site | Fort Myers | Florida | 33916 | — |
| GSK Investigational Site | Miami | Florida | 33143 | — |
| GSK Investigational Site | Miami | Florida | 33156 | — |
| GSK Investigational Site | Ocala | Florida | 34474 | — |
| GSK Investigational Site | Pembroke Pines | Florida | 33024 | — |
| GSK Investigational Site | Sarasota | Florida | 34237 | — |
| GSK Investigational Site | Atlanta | Georgia | 30309 | — |
| GSK Investigational Site | Melrose Park | Illinois | 60160 | — |
| GSK Investigational Site | Indianapolis | Indiana | 46254 | — |
| GSK Investigational Site | Jeffersonville | Indiana | 47130 | — |
| GSK Investigational Site | Newburgh | Indiana | 47630 | — |
| GSK Investigational Site | Lexington | Kentucky | 40509 | — |
| GSK Investigational Site | Albany | New York | 12205 | — |
| GSK Investigational Site | Kingston | New York | 12401 | — |
| GSK Investigational Site | Poughkeepsie | New York | 12601 | — |
| GSK Investigational Site | Salisbury | North Carolina | 28144 | — |
| GSK Investigational Site | Winston-Salem | North Carolina | 27103 | — |
| GSK Investigational Site | Springfield | Oregon | 97477 | — |
| GSK Investigational Site | Bala-Cynwyd | Pennsylvania | 19004 | — |
| GSK Investigational Site | Lancaster | Pennsylvania | 17604 | — |
| GSK Investigational Site | Sellersville | Pennsylvania | 18960 | — |
| GSK Investigational Site | Providence | Rhode Island | 02906 | — |
| GSK Investigational Site | Simpsonville | South Carolina | 29681 | — |
| GSK Investigational Site | Nashville | Tennessee | 37232 | — |
| GSK Investigational Site | Dallas | Texas | 75234 | — |
| GSK Investigational Site | Richmond | Virginia | 23294 | — |
| GSK Investigational Site | Tacoma | Washington | 98405 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 17 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00321477, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 19, 2017 · Synced Sep 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00321477 live on ClinicalTrials.gov.